Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca's Brilique Cleared In NICE's Initial Appraisal

This article was originally published in The Pink Sheet Daily

Executive Summary

The U.K.'s cost regulator, NICE, clears AstraZeneca's antiplatelet drug ticagrelor for use in the National Health Service in a preliminary assessment.

You may also be interested in...



Germany's IQWiG Gives Partial Nod To AZ's Brilinta In First Added-Benefit Assessment

AstraZeneca's clot buster could benefit certain patients with Acute Coronary Syndromes, Germany's health technology assessors conclude.

Germany's IQWiG Gives Partial Nod To AZ's Brilinta In First Added-Benefit Assessment

AstraZeneca's clot buster could benefit certain patients with Acute Coronary Syndromes, Germany's health technology assessors conclude.

AstraZeneca Gives FDA More Data On Brilinta Interaction With High-Dose Aspirin

In replying to FDA's December "complete response," company reaffirms its view that U.S. efficacy in the pivotal PLATO study was undercut by high doses of concomitant aspirin.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS072455

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel